US Plans Up to 200% Tariffs, Forcing Indian Pharma Firms to Prepare for Relocation

Summary

US President Trump announced a phased tariff plan on imported generic drugs, offering a two-year zero-tariff grace period followed by a 100% tariff in August 2028 and 200% in 2029 for manufacturers that fail to relocate production to the U.S. Zhitong+ 2. Indian pharmaceutical stocks, including Aurobindo and Lupin, fell sharply as the industry, which operates on thin 4-6% margins, faces potential exclusion from its largest market Reuters. The policy also aims to reduce reliance on Chinese APIs, which currently supply 70% of India’s needs .

Impact Analysis

So, Trump is basically handing Indian pharma an ‘adapt or die’ ultimatum. A 200% tariff on businesses with 4-6% margins isn’t a tax—it’s an eviction notice . The two-year buffer is a red herring; building FDA-compliant U.S. plants takes years and massive capex that these players simply can’t afford without a total pricing overhaul .

What the market is starting to price in—but perhaps underestimating—is the structural attack on the Sino-Indian axis. India is the middleman, sourcing 70% of APIs from China . By forcing ‘壓片灌裝’ (tableting and filling) to the U.S., the administration is setting the stage for mandatory U.S. or ‘friendly’ API sourcing later.

Bottom line: the era of ultra-cheap Indian generics is ending. I’d avoid Indian exporters lacking U.S. footprints and instead look at domestic U.S. players or those with existing U.S. capacity who just gained a massive competitive moat. Also, watch for a margin squeeze in U.S. healthcare providers as generic costs inevitably spike Reuters.